Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review
US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...
NYSE: NUVB
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures
U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based...